For Q1 FY2026 ended March 31, 2026, Definium Therapeutics reported a net loss of $77.1 million, a 230% increase from the prior year. Operating loss was $59.2 million, up 84%. Diluted EPS was -$0.71, a 103% decline. The company held $262.5 million in cash and $278.8 million in equity, with $40.8 million in long-term debt.
•Net loss widened to $77.1 million from $23.3 million in Q1 FY2025.
•Operating loss increased 84% to $59.2 million.
•Diluted EPS fell to -$0.71 from -$0.35 year-over-year.
•Cash and equity stood at $262.5 million and $278.8 million, respectively.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Definium Therapeutics, Inc., a clinical biopharmaceutical company develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and brain health disorders DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Formerly known as Mind Medicine (MindMed) Inc., the company rebranded as Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Definium Therapeutics, Inc. is a clinical biopharmaceutical company focused on developing novel product candidates to treat brain health disorders. Its lead product candidate, DT120, is in phase 3 clinical trials for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders. Another key candidate, DT402, is a R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA) currently in phase 2a clinical trials for the treatment of autism spectrum disorder. The company operates in the biotechnology industry within the healthcare sector and is headquartered in New York, New York.
On which exchange is Definium Therapeutics (DFTX) listed and what currency is used?
Definium Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol DFTX. The company's stock is traded in U.S. dollars (USD). As a U.S.-based company, its financial reporting and share pricing are denominated in USD, making it accessible to investors on major U.S. stock exchanges.
What sector and industry does Definium Therapeutics (DFTX) belong to?
Definium Therapeutics operates in the healthcare sector, specifically within the biotechnology industry. As a clinical biopharmaceutical company, it focuses on developing therapies for brain health disorders, which falls under the broader biotechnology umbrella. The company's research and development efforts are centered on novel product candidates targeting psychiatric and neurological conditions, positioning it within the biotech subsector of healthcare.
Where is Definium Therapeutics (DFTX) headquartered and what is its history?
Definium Therapeutics, Inc. is headquartered in New York, New York, United States. The company was formerly known as Mind Medicine (MindMed) Inc. and rebranded to Definium Therapeutics, Inc. in January 2026. This rebranding reflects a strategic shift in focus, though the company continues to develop treatments for brain health disorders. Its primary markets are in the United States, where it conducts clinical trials and seeks regulatory approvals.
What are the main product candidates of Definium Therapeutics (DFTX)?
Definium Therapeutics has two main product candidates in its pipeline. DT120 is the lead candidate, currently in phase 3 clinical trials for generalized anxiety disorder, major depressive disorder, and other brain health disorders. DT402 is a R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA) and is in phase 2a clinical trials for the treatment of autism spectrum disorder. Both candidates target significant unmet needs in brain health, with DT120 addressing common mood disorders and DT402 focusing on a specific neurodevelopmental condition.